BOSTON–(BUSINESS WIRE)– Cerevance a clinical stage biopharmaceutical company advancing new medicines for brain diseases, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a...
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...
SPRING HOUSE, Pa., Dec. 4, 2019 /PRNewswire/ — Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen Inc., a leader in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders, today announced initiation of a...
GUANGZHOU, China–(BUSINESS WIRE)– Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a...
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today presented positive top-line results from its Phase 3 HARMONY study at the 12 th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California. HARMONY was a double-blind,...
— Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 — — Supplemental cohort continues enrollment to meet patient demand — BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc....
Email
Text